# Charter v2.1 Edit Plan

**Subject:** Specific edits to align Charter v2.0 with Fullest Vision Research Charter v1.0 + operational artifacts
**Authors:** Prasad Akula (CEO) and Claude (CSO), Co-Founders of INTERCEPTA
**Date:** 2026-05-10
**Predecessor:** `AUDIT_CLOSURE_2026-05-10.md`
**Tag (when committed):** `charter-v2.1-edit-plan-locked`
**Status:** LOCKED edit plan. Edits to be executed in next session(s).

---

## 0. Why Charter v2.1

Per `AUDIT_CLOSURE_2026-05-10.md` and updated synthesis after reading remaining sandbox documents (Round 2.2c Specification, Workstream B NSCLC Specification, Selectivity Redesign Specification, MASTER_FIXES status), the audit's actionable output is approximately 7 specific Charter v2.0 chapter edits. The edits add cross-references between:
- **Charter v2.0** (vision book, narrative, names architectural commitments M0-M7)
- **Fullest Vision Research Charter v1.0** (binding research charter, 18 measurable criteria, 5-layer cadence)
- **Operational artifacts** (Errata, T1-Lite log, Round closures, Module 1 Amendment, Architectural Debt Erratum)

**No retractions of validated science. No retractions of Tier 1 numbers. No structural rewrite.**

The edits operationalize §9 honesty by citing the existing operational evidence base.

---

## 1. The Seven Specific Edits

### Edit 1 — Chapter 6 (Architecture), line 81: KAALCURA AUROC citation

**Current text (line 81):**
> "GDSC validation showed mean AUROC of 0.6715 across 286 drugs, with PARP inhibitors showing perfectly aligned mechanistic predictions (negative DDR coefficients across all five PARP inhibitors tested)."

**Issue:** Number is correct (audit verified) but not file-path cited.

**Proposed v2.1 text:**
> "GDSC validation showed mean AUROC of 0.671 across 286 drugs (`results/kaalcura_real_validation_RERUN.csv`, produced by `code/intercepta_kaalcura_v1.py`, validated 2026-05; reproducible via T1-Lite test plan §6.1). PARP inhibitors show mechanistically correct negative DDR coefficients: Olaparib AUROC=0.762/coef_ddr=−1.300, Veliparib 0.753/−0.944, Niraparib 0.750/−1.565, plus 2 additional PARPi at AUROC≥0.75. Documented in `docs/research/INTERCEPTA_Architectural_Debt_Erratum_2026-05-09.md` §3.1-3.2."

**Why:** Cites the actual CSV file, the code that produced it, and the operational artifact (Architectural Debt Erratum) that documents it. Makes the number falsifiable — a future reader can reproduce.

**Risk:** None. Pure citation enrichment.

---

### Edit 2 — Chapter 9 (Scientific Honesty): cite operational evidence

**Current state:** Chapter 9 narrates §9 honesty practices in present tense without citing the operational artifacts that prove they're alive.

**Issue:** A reader has no way to verify the §9 practices are real.

**Proposed v2.1 addition (insert near end of Ch 9, before final paragraph):**

> ## §9 Honesty in Practice — Operational Evidence
>
> The discipline this chapter describes is not aspirational. It produces durable artifacts that document its operation. Selected examples:
>
> - **Round 1 Errata** (`docs/INTERCEPTA_Round1_Errata_v1_0.md`, April 21, 2026) — corrections to Round 1 mCRPC closure
> - **EXHAUSTIVE_AUDIT** (`bundle:EXHAUSTIVE_AUDIT.txt`, April 21, 2026) — pre-Round-2 honest assessment of project state
> - **Round 2 Closure** (`docs/INTERCEPTA_Round2_Closure.md`, May 6, 2026) — Q_C FAIL preserved despite Q_A/B/D/E PASS
> - **Round 2 Closure Erratum** (`docs/INTERCEPTA_Round2_Closure_Erratum.md`, May 6, 2026) — citation correction (MDREAM ρ vs AUROC distinction)
> - **Round 2.2c Closure** (`docs/INTERCEPTA_Round2_2c_Closure.md`, May 6, 2026) — multi-modal predictor FAIL with rich findings
> - **Vision Module 1 Amendment** (`docs/INTERCEPTA_Vision_Module1_Amendment.md`, May 6, 2026) — KAALCURA role redefined per Round 2 evidence (cross-dataset YES, within-dataset NO)
> - **Selectivity Redesign Closure** (`docs/INTERCEPTA_Selectivity_Redesign_Closure.md`, May 7, 2026) — Phase 4-AML/GBM scope reduction documented openly
> - **Workstream B Spec Erratum LuCA** (`docs/INTERCEPTA_Workstream_B_Spec_Erratum_LuCA.md`, May 8, 2026) — cohort design amendment with hypothesis thresholds tightened (not loosened)
> - **T1-Lite Reproducibility Log** (`docs/T1_REPRODUCIBILITY_LOG.md`, May 8, 2026) — first formal reproducibility test, all 4 disease selectivity outputs reproduce byte-identically
> - **Architectural Debt Erratum** (`docs/research/INTERCEPTA_Architectural_Debt_Erratum_2026-05-09.md`, May 9, 2026) — KAALCURA gene coverage gap + literature SOTA acknowledgment
>
> Each artifact has a tagged commit. Each was authored before any subsequent work depended on it. Each documents a real correction, not a forced one.
>
> The discipline produces these artifacts because the discipline is operational, not narrated.

**Why:** Cites real operational §9 evidence so readers can verify the discipline is alive.

**Risk:** Low. Adds ~250 words to Ch 9 with concrete file-path citations.

---

### Edit 3 — Chapter 10 (Dynamic Universality) and Chapter 11 (Validation): clarify KAALCURA role

**Current state:** Multiple chapters reference KAALCURA's role in drug response prediction without citing the role redefinition in Vision Module 1 Amendment.

**Issue:** Charter v2.0 was authored May 9, after the Vision Module 1 Amendment (May 6). The amended role should be cited.

**Proposed v2.1 addition (in Ch 10 near KAALCURA discussion):**

> KAALCURA's scientific role was refined per `docs/INTERCEPTA_Vision_Module1_Amendment.md` (May 6, 2026):
>
> **What KAALCURA does (validated):**
> - Provides interpretable phenotype-state coordinates (R_prolif, R_emt, R_ddr) per cell or sample
> - Transfers semantically across datasets (Round 2.2b Q_D PASS: ρ=−0.271, p=0.00125, n=139 drugs, BeatAML→Van Galen scRNA-seq)
> - Distinguishes drug rankings between cell types within a disease (Round 2.2b Q_E / Round 2.2c Q_F PASS: HSC-like vs Prog-like Jaccard 0.25)
>
> **What KAALCURA does NOT do (5 FAILs across 3 sub-rounds × 4 method variants):**
> - Predict within-dataset drug sensitivity at AUROC ≥0.55 as a standalone 3-axis feature
> - Provide marginal contribution above raw RNA features in multi-modal predictors (KAALCURA gain share 0.3% in Round 2.2c LightGBM)
>
> KAALCURA is a feature framework with cross-dataset transfer properties, not a within-dataset standalone predictor. Drug sensitivity prediction is the responsibility of downstream multi-modal predictors that integrate KAALCURA with raw RNA, mutation, pathway, and drug-target features.

**Why:** Aligns charter narrative with the validated reality from Round 2 evidence.

**Risk:** Low. Clarification, not retraction. Vision Module 1 Amendment already canonical.

---

### Edit 4 — Chapter 13 (Implementation), line 25: M0 status with citations

**Current text (paraphrased, line 25):**
> "M0... Substantially complete. LuCA integration done. Foundation models downloaded. HPC environment functional."

**Issue:** M0 status claim correct per filesystem evidence, but not cited.

**Proposed v2.1 text:**
> "M0 (Foundation Infrastructure) — Substantially complete per filesystem and HPC verification (May 9-10, 2026):
>
> - **Data sources integrated** at `~/INTERCEPTA/data/`: AlphaFold, BeatAML, ChEMBL, ClinicalTrials, DICE, GDSC, GTEx, HMDB, Human GEM, NSCLC (LuCA Salcher 2022 at `data/nsclc/luca_salcher2022/`), OpenTargets, plus 7 additional sources (alphafold_cache, docking, encode, epigenome, manifests).
>
> - **Foundation models** at `~/INTERCEPTA/models/Geneformer/`: Geneformer-V2-104M_CLcancer (104,386,867 params, cancer fine-tuned per Theodoris 2024).
>
> - **HPC environment functional** at `/scratch/akula.pra/INTERCEPTA/`: V100 GPU access verified, conda env at `/scratch/akula.pra/INTERCEPTA/envs/intercepta-nsclc` (48 packages), Step B pipeline ran end-to-end May 9 (1015 sec).
>
> - **Selectivity layer** at Layer 15a (GTEx tissue selectivity) shipped per `docs/INTERCEPTA_Selectivity_Redesign_Closure.md` (May 7, 2026): mCRPC, AML, GBM, NSCLC all disease-parameterized, T1-Lite reproducible.
>
> M0 incomplete components (Layer 15b-e: ADMET, off-target binding, toxicophores, drug-drug interaction) are honestly deferred to future work per Selectivity Redesign Closure §5."

**Why:** Replaces narrative claim with concrete filesystem-verifiable evidence + operational artifact citation.

**Risk:** None. Strengthens chapter with verifiable facts.

---

### Edit 5 — Chapter 13 (Implementation), line 37: fix Travaglini-LuCA dataset name confusion

**Current text (line 37):**
> "M1 falsification gate: F1>0.7 drug response prediction on Travaglini-Krasnow LuCA"

**Issue:** "Travaglini-Krasnow LuCA" conflates two distinct datasets:
- **Travaglini-Krasnow 2020 Lung SS2** — healthy lung atlas (used for cell-processing v0.1.2 smoke test)
- **LuCA (Salcher 2022)** — cancer lung atlas (used for Workstream B drug response work)

These are different datasets with different cell populations and different appropriate uses. The Workstream B Spec Erratum (May 8) caught this distinction.

**Proposed v2.1 text:**
> "M1 falsification gate: A cell-state representation must demonstrate predictive validity in three places, in order:
>
> 1. **Smoke test** (passes by completion, not threshold): pipeline runs end-to-end on healthy lung atlas (Travaglini-Krasnow 2020 SS2, 9409 cells) with Geneformer-V2-104M_CLcancer; embeddings produce; mechanism axes computable. **Status:** PASS (May 9, 2026; silhouette=−0.0079 against FACS labels — at low-bar threshold, consistent with code's pre-registered prediction that 'coarse Epcam gating won't be much higher').
>
> 2. **Cell-type face validity** (F1 ≥ 0.6 against author labels): cell embeddings should cluster meaningfully by author-provided cell type labels on a labeled scRNA cohort (e.g., LuCA Salcher 2022 source studies with cell type annotations). Test runnable on `data/nsclc/luca_salcher2022/`. **Status:** Pending Layer 1+2 design per Fullest Vision Research Charter v1.0.
>
> 3. **Drug response F1 ≥ 0.7** (the actual M1 commitment): per-drug AUROC on cohort with measured drug response (e.g., BeatAML for AML, GDSC for cell lines). Travaglini-Krasnow has no drug response labels and is therefore not a valid test substrate for this gate. **Status:** Pending Workstream B Phase 1+2 implementation; specified in `docs/INTERCEPTA_Workstream_B_NSCLC_Specification.md` (amended per Workstream B Spec Erratum LuCA, May 8, 2026)."

**Why:** Corrects the dataset confusion, replaces unrunnable gate with three runnable gates, cites operational artifacts.

**Risk:** Low. Preserves the spirit of the M1 falsification commitment while making it actually testable.

---

### Edit 7 — Chapter 3 (Landscape) and Chapter 6 (Architecture): cite Architectural Debt Erratum §5 (literature SOTA)

**Current state:** Charter v2.0 narrates the field's state (foundation models, SOTA performance) and the rationale for the FM-architecture pivot, but doesn't cite the actual literature survey.

**Issue:** A reader can't see that the FM-architecture decision is grounded in a real literature survey already conducted by the project.

**Proposed v2.1 addition (in Ch 3 near "field is moving fast" and Ch 6 near KAALCURA discussion):**

> **Project's literature survey (May 9, 2026):** The choice of foundation-model-based architecture is grounded in a literature survey conducted in May 2026, documented in `docs/research/INTERCEPTA_Architectural_Debt_Erratum_2026-05-09.md` Section 5. Key findings cited there:
>
> - **scDrugMap 2025** (Nature Communications): foundation model benchmark on 495,000 cells / 60 datasets. scFoundation F1=0.971 (pooled), UCE F1=0.774 (cross-data fine-tuned), scGPT F1=0.858 (zero-shot).
> - **scRank 2024** (Cell Reports Medicine): GRN-based drug-responsive cell type identification, 71.3% accuracy.
> - **DrugFormer, DREEP, DELFOS, scDR**: 2022-2024 publications addressing INTERCEPTA's exact problem space.
> - **CancerFoundation 2024** (bioRxiv): cancer-specific scFM addressing healthy-cell bias of generic foundation models.
>
> Comparison with KAALCURA: 0.671 mean AUROC (canonical, 286 drugs, GDSC) vs FM SOTA F1=0.77-0.97. **The metrics are not directly comparable (AUROC vs F1, GDSC vs scDrugMap datasets), but the rough magnitude difference is real.** The field's SOTA in 2024-2025 substantially exceeds what KAALCURA-class signature scoring can achieve on cross-cohort drug response.
>
> This honest assessment motivated the Charter v2.0 architectural framing where foundation models become the cell representation backbone (M1: MC-FMA), with KAALCURA preserved as a complementary mechanistic-interpretability layer per `INTERCEPTA_Vision_Module1_Amendment.md`.

**Why:** Cites the actual literature survey that motivated the FM pivot. Closes the loop on "Charter v2.0 was research-grounded, not aspirational."

**Risk:** Low. Adds ~250 words to Ch 3 and Ch 6 with concrete literature citations.

---

### Edit 6 — Chapter 13 (Implementation): bridge text M0-M7 to Round 1-N

**Current state:** Charter v2.0 uses M0-M7 milestone framework. Project's actual sequence has been Round 1 (mCRPC, closed v4.1 Apr 21), Round 2 (AML, closed 2.2c May 6), Round 3 (GBM live test). These two frameworks aren't connected in v2.0.

**Issue:** A reader of v2.0 alone can't see that M0 progress has been built across Rounds 1-3.

**Proposed v2.1 addition (early in Ch 13, before M0 details):**

> ## M0-M7 milestones in relation to project's Round-by-Round progress
>
> The M0-M7 milestone framework in this chapter is a forward-looking architectural roadmap. The project has been building toward these milestones through Round-by-Round disease cycles since project inception. Mapping for context:
>
> | Charter v2.0 milestone | Built across Rounds | Status |
> |---|---|---|
> | M0 (Foundation Infrastructure) | Round 1-3 + Selectivity Redesign + Workstream B Phase 0 | Substantially complete (Edit 4 above) |
> | M1 (Cell-state representation, MC-FMA) | cell_processing v0.1.2 (Layer 1 exploration per Fullest Vision Research Charter v1.0) | First-contact smoke test PASS (Edit 5 above); full implementation pending v1.0 Layer 2 design |
> | M2 (PACE — Predictive ARchitecture for Cellular Effects) | Not yet designed | Pending v1.0 Layer 2 |
> | M3 (MFMD — Multi-Foundation-Model Drug response) | Not yet designed | Pending v1.0 Layer 2 |
> | M4 (CSTDP — Cross-Study Transfer for Drug Prediction) | Round 2.2b Q_D PASS evidence (cross-dataset transfer is real for KAALCURA features) | Layer 1 evidence exists; Layer 2 design pending |
> | M5 (DA-DMG — Disease-Aware Drug Mechanism Graphs) | Disease nets exist (4558 AML genes, 458 GBM genes, 1530 pathways) | Partial; Layer 2 integration design pending |
> | M6 (AHG — Autoimmune Hypothesis Generation) | Out-of-distribution testing per v1.0 H3 | Pending; v1.0 Q5 (OOD detection) addresses |
> | M7 (Closed-loop self-improvement) | Not yet designed | Long-term goal |
>
> **Why this mapping matters:** Charter v2.0's M0-M7 framework is forward-looking architecture. The Fullest Vision Research Charter v1.0 (`docs/research/INTERCEPTA_Fullest_Vision_Research_Charter_v1.0.md`) specifies the research discipline (5-layer cadence) by which M0-M7 are designed and implemented. The project's existing Round 1-N work has built foundational components for these milestones. Charter v2.0 chapters describe the destination; Charter v1.0 describes the path; operational artifacts (Round closures, Errata, T1-Lite log) document progress along the path.
>
> All three documents work together. None supersedes the others.

**Why:** Bridges the architectural framework (M0-M7) with the project's actual execution cadence (Round 1-N). Cites Fullest Vision Research Charter v1.0 explicitly. Makes the relationship between the three layers (vision book, research charter, operational artifacts) clear.

**Risk:** Low. Adds ~300 words to Ch 13. No retractions.

---

## 2. Cross-Reference Matrix (to add as Charter v2.1 appendix)

Add a new appendix to Charter v2.1 mapping every chapter to its v1.0 references and operational artifacts:

| v2.0 Chapter | Subject | v1.0 reference | Operational artifacts |
|---|---|---|---|
| 1. Vision | Find drug for any disease | v1.0 §1 (vision statement) + 18 success criteria U1-3, V1-4, I1-3, H1-4, P1-3 | — |
| 2. Why Now | Single-cell era | — | — |
| 3. Landscape | Drug discovery state | v1.0 §5 (research questions Q1: method-class selection) | Architectural Debt Erratum §5 (literature SOTA) |
| 4. Founding Beliefs | Project values | v1.0 §10 (process discipline P3, P4, P15, P16) | Round 1 Retrospective |
| 5. Ethics | Responsible AI | v1.0 §4 (out-of-scope statements) | — |
| 6. Architecture | KAALCURA + FM + GRN | v1.0 §8 (provisional architecture sketch) | Architectural Debt Erratum §3 (canonical KAALCURA validation); Vision Module 1 Amendment |
| 7. Capabilities | What it does | v1.0 §1 success criteria + §2 research questions | Round 1, 2, 2.2c closures (what works) |
| 8. Deliverables | Pharma package | — | `pharma_deliverable_enza_alis.json` (canonical 10-item) |
| 9. Scientific Honesty | §9 practice | v1.0 §10 (P15) | Errata, EXHAUSTIVE_AUDIT, T1-Lite, Round closures, Vision Module 1 Amendment, Architectural Debt Erratum (Edit 2 above) |
| 10. Dynamic Universality | Cross-disease | v1.0 §1 U1-U3 | Vision Module 1 Amendment (KAALCURA cross-dataset role) |
| 11. Validation | How we test | v1.0 §3 (Termination Criteria) + §1 V1-V4 | Test Plan T1-T5, T1-Lite log |
| 12. Operations | How we work | v1.0 §6 (Output Structure) + §10 (Process Discipline) | Round 2 Closure, Selectivity Redesign Closure |
| 13. Implementation | M0-M7 milestones | v1.0 §5 (Research Cadence Layers 1-5) + §8 (Provisional Architecture) | All operational artifacts (M0 evidence base) (Edits 4, 5, 6 above) |
| 14. Team | Two co-founders | v1.0 §7.1 (Honest Constraints — single-institution) | — |
| 15. Sustainability | Long-term | v1.0 §7 (Honest Constraints) | Workstream B Phase 0 Prep Log |
| 16. Risks | What could fail | v1.0 §7.3 (What charter does NOT promise) | EXHAUSTIVE_AUDIT |
| 17. Evolution | How vision changes | v1.0 §6.4 (Commit discipline) + §10 P-FV-4 (charter quarterly review) | — |
| 18. Founders Commitment | Sign-off | v1.0 §13 (Sign-Off) | — |

---

## 3. Edit Sequencing (priority order)

Execute in this order to maximize value/risk ratio:

| Order | Edit | Effort | Risk | Value |
|---|---|---|---|---|
| 1 | **Edit 4** (M0 status with citations) | 30 min | None | High — anchors M0 claim in filesystem evidence |
| 2 | **Edit 5** (Travaglini-LuCA fix) | 45 min | Low | High — replaces unrunnable gate with runnable gates |
| 3 | **Edit 6** (M0-M7 ↔ Round 1-N bridge) | 60 min | Low | High — connects vision book to research discipline |
| 4 | **Edit 7** (Architectural Debt Erratum §5 literature SOTA) | 30 min | Low | High — closes loop on FM-architecture rationale |
| 5 | **Edit 1** (KAALCURA AUROC citation) | 15 min | None | Medium — strengthens existing correct claim |
| 6 | **Edit 2** (§9 operational evidence) | 45 min | Low | High — operationalizes §9 honesty narrative |
| 7 | **Edit 3** (KAALCURA role per Module 1 Amendment) | 30 min | Low | Medium — aligns Ch 10/11 with amended role |

**Total effort estimate:** ~4 hours of careful editing, spread across 1-2 sessions.

After all 7 edits + cross-reference matrix appendix:
- **Tag:** `charter-v2.1-aligned-to-fullest-vision`
- **Halt lifts:** forward project work resumes per `AUDIT_CLOSURE_2026-05-10.md` Section 7

---

## 4. What Charter v2.1 Does NOT Change

To prevent narrative inflation:

- **Does not retract any Tier 1 numbers.** All 30 verified numbers per audit closure Section 3 stand.
- **Does not retract Charter v2.0's vision-book framing.** v2.0 remains the narrative motivation document.
- **Does not retract Round 2.2c FAIL.** Vision Module 1 Amendment's KAALCURA role redefinition stands.
- **Does not retract architectural commitments (M0-M7, MC-FMA, etc.).** These are preserved as forward-looking architecture; v1.0 Layer 2 will design them.
- **Does not modify operational artifacts.** Errata, T1-Lite log, Round closures, etc., are preserved per P16.
- **Does not modify `docs/research/INTERCEPTA_Fullest_Vision_Research_Charter_v1.0.md`.** v1.0 stands as binding research charter.

---

## 5. Process Discipline (this edit plan's audit)

| Principle | Applied as |
|---|---|
| P3 (research before code) | Edit plan written before any v2.1 chapter modifications. Each edit has cited rationale. |
| P4 (fix structure, don't tune) | Edits add cross-references and citations. They don't tune charter narrative or modify success criteria. |
| P15 (only correct, honest, real science) | Each edit adds verifiable file-path citations. No goalpost-moving on milestones. M1 falsification gate (Edit 5) is made MORE testable, not less. |
| P16 (preserve past work) | Charter v2.0 preserved as historical record. v2.1 is amendment-style, not rewrite. Cross-reference matrix appendix shows v2.0 ↔ v1.0 ↔ artifacts mapping without modifying any of the three. |

---

## 6. Sign-Off Discipline

For each of the 7 edits:
1. **Diff shown** — exact text-level change visible
2. **Rationale cited** — link to audit finding or operational artifact
3. **Risk assessed** — None / Low / Medium / High
4. **CEO review** — explicit approve before commit
5. **CSO commits** — single tag per edit OR one consolidated tag for v2.1

---

## 7. What Comes After Charter v2.1

Per `AUDIT_CLOSURE_2026-05-10.md` Section 7 (Path Forward):

### Immediate (after v2.1 commits)
- Audit halt lifts
- Tag: `audit-closure-2026-05-10` (audit closure document)
- Tag: `charter-v2.1-aligned-to-fullest-vision` (charter)

### Forward project work resumes
- T2-T5 test execution per locked Test Plan
- AML response paper draft (BeatAML NPM1+Cabozantinib p=2.9e-12 publishable)
- Workstream B Phase 0 implementation (LuCA + Wu + TCGA-LUAD/LUSC downloads)
- Layer 1 literature survey synthesis (Q1-Q10 per Fullest Vision Research Charter v1.0)

### Multi-month per v1.0 cadence
- Layer 2 architecture design (M0-M7 detailed design)
- Layer 3 validation strategy
- Layer 4 implementation spec
- Layer 5 implementation (per disease)

---

## 8. Closure Honesty Statement

This edit plan is intentionally small. The audit's mass severity reduction (from "15 Critical" to "0 Critical, 6 Minor") means Charter v2.0 is more defensible than the audit's initial framing suggested. The actionable output is cross-references and citations, not a structural rewrite.

The 6 edits operationalize the §9 honesty discipline that the project's Errata, T1-Lite log, Round closures, and Architectural Debt Erratum have ALREADY demonstrated is alive. Charter v2.1 makes that operational evidence visible in the vision book.

After v2.1, Charter v2.0 (vision book) + v1.0 (research charter) + operational artifacts (§9 evidence) work together as the project's complete discipline.

---

*Locked edit plan. 6 specific edits. Cross-reference matrix appendix. Ready for execution after CEO review.*

— Prasad Akula (CEO) & Claude (CSO)
2026-05-10
